Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

What are 10K annual reports?

10K reports are comprehensive annual reports filed by public companies with the SEC, containing detailed financial statements, business operations, risk factors, and management discussion.

How often are annual reports updated?

Annual reports are typically filed once per year, usually within 60-90 days after the company's fiscal year end. We update our database as soon as new reports become available.

How do I analyze VNDA stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate VNDA investment potential.

What is VNDA stock price today?

Get real-time VNDA stock price, historical data, and price charts on Financhill. Track VNDA performance with our advanced analysis tools.

Is VNDA a good investment?

Evaluate VNDA investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy VNDA stock?

To buy VNDA stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of VNDA?

View detailed market capitalization data and company valuation metrics for VNDA on our comprehensive analysis page.

What is the P/E ratio of VNDA?

Use our fundamental analysis tools to view VNDA P/E ratio and compare valuation metrics with industry peers.

What are VNDA earnings?

View VNDA earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

Vanda Pharmaceuticals, Inc. 10K Form

Buy

VNDA
Vanda Pharmaceuticals, Inc.

Last Price:

$5.21

Seasonality Move:

-1.83%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-09	10Q	VNDA/Vanda Pharmaceuticals, Inc. Quarterly
2023-11-09	10Q	VNDA/Vanda Pharmaceuticals, Inc. Quarterly
2023-07-28	10Q	VNDA/Vanda Pharmaceuticals, Inc. Quarterly
2023-05-03	10Q	VNDA/Vanda Pharmaceuticals, Inc. Quarterly
2022-11-03	10Q	VNDA/Vanda Pharmaceuticals, Inc. Quarterly
2022-08-04	10Q	VNDA/Vanda Pharmaceuticals, Inc. Quarterly

Receive VNDA News And Ratings

See the #1 stock for the next 7 days that we like better than VNDA

VNDA Financial Statistics

Sales & Book Value

Annual Sales:	$198.8M
Cash Flow:	$-31.8M
Price / Cash Flow:	0
Annual Sales:	$7.89
Price / Book:	0.67

Profitability

EPS (TTM):	-1.43150
Net Income (TTM):	$-84.2M
Gross Margin:	$180.2M
Return on Equity:	-16.55%
Return on Assets:	-13.33%

Vanda Pharmaceuticals, Inc. Earnings Forecast

Key Vanda Pharmaceuticals, Inc. Financial Ratios

The Gross Profit Margin over the past 19 years for VNDA is 90.65%.
The Selling, General & Administrative Expenses for VNDA have been equal to 73.66% of Gross Profit Margin.
The Research & Development expenses have been 37.45% of Revenue.
The Net Earning history of VNDA is -9.51% of Total Revenues.
Per Share Earnings over the last 21 years have been positive in 11 years.

Vanda Pharmaceuticals, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange:	NASDAQ
Industry:	Biotechnology
Sector:	Health Care
Current Symbol:	VNDA
CUSIP:	921659
Website:	vandapharma.com

Debt

Debt-to-Equity Ratio:	0.02
Current Ratio:	3.12
Quick Ratio:	2.92

Price-to-Earnings

Trailing P/E Ratio:	110.5
Forward P/E Ratio:	0

VNDA Technical Analysis vs Fundamental Analysis

Buy

Vanda Pharmaceuticals, Inc. (VNDA) is a Buy

Is Vanda Pharmaceuticals, Inc. a Buy or a Sell?

Vanda Pharmaceuticals, Inc. stock is rated a Buy

The current Vanda Pharmaceuticals, Inc. [VNDA] share price is $5.27. The Score for VNDA is 62, which is 24% above its historic median score of 50, and infers lower risk than normal.